since the outset. UNITAID is hosted by the World Health Organization and finances
programmes for access to health products (treatments, diagnostic tests and preventive tools)
to treat the three major pandemics: HIV/Aids, Malaria and Tuberculosis. UNITAID is most
active in Africa as at least 85% of its funding is channelled towards the least developed
countries. What is unique about UNITAID is that it has chosen to act on public health by
remedying market shortcomings such as high prices, supplier monopolies and stock
shortages. UNITAID develops a product driven approach complementary to the country
driven approach of the Global Fund. In practice, the aim of UNITAID’s actions is to lower
prices, speed up the development of more suitable medications and improve the quality and
availability of health projects (market shaping).
Since 2006, funds from UNITAID, and thus from the French airline-ticket levy, have enabled:
- the creation of a previously non-existent market for anti-HIV paediatric medication;
- 400,000 children living with HIV to receive treatment, i.e. 75% of worldwide cases;
- the stabilization of a market for second-line anti-HIV reducing by up to 60% the price
of medication;
- HIV screening for eight million pregnant women;
- the treatment of over 800,000 HIV-positive pregnant women in order to prevent
mother to child transmission of HIV;
- the financing of high-tech laboratory facilities to detect forms of multi-drug-resistant
tuberculosis in eight high-prevalence countries;
- the distribution of 1.5 million first and second-line treatments in 72 countries; UNITAID
is the world’s largest supplier of paediatric medication against tuberculosis;
- the provision of 200 million artemisinin-based combination therapies (ACTs), the most
effective treatment against malaria;
- the creation of ACT markets in seven countries where malaria is endemic through an
innovative subsidization approach which enables prices to be lowered from 25 cents
to 2$ per ACT (as opposed to their former price of 6 to 8 euros);
One dollar invested in UNITAID represents:
- a HIV screening kit for a pregnant woman;
- vital anti-malaria treatment for two children;
- a day of HIV treatment for an adult;
- a week of treatment against tuberculosis;
- a week of HIV treatment for a child.
b) IFFIm/GAVI:
GAVI was launched in January 2000 in order to improve and facilitate vaccination in the
poorest developing countries and to increase their access to new vaccinations. Since 2006,
GAVI's major source of funding has been the IFFIm (International Finance Facility for
Immunization). IFFIm uses pledges from donor governments to sell bonds in the capital
markets, making funds immediately available for GAVI programmes.
By the end of 2011, GAVI:
- has contributed to avoid over 5.5 million deaths ;
- had supported the immunization of over 325 million additional children;
c) Global Fund to fight AIDS, Tuberculosis and Malaria:
The Global Fund is a Swiss foundation based on an international public-private partnership
whose mission is to raise and disburse funds towards the prevention and treatment of AIDS,
tuberculosis and malaria.
The Fund carries out vital work towards the achievement of the health-based MDGs, in
particular MDG 6: “Combat HIV/Aids, malaria and other diseases”. The Global Fund alone